Media Articles Related to Eldepryl (Selegiline)
Possible new target for monitoring Parkinson's disease
Source: Genetics News From Medical News Today [2014.04.14]
Scientists may have discovered how the most common genetic cause of Parkinson's disease destroys brain cells and devastates many patients worldwide.
Could blueberries help treat Parkinson's disease?
Source: Nutrition / Diet News From Medical News Today [2014.04.14]
Blueberries are deemed one of the healthiest foods because of their richness in antioxidants. Now, researchers say the fruit may help to treat patients with Parkinson's disease.
Gene Therapy May Hold Promise for Advanced Parkinson's Disease
Source: MedicineNet Tremor Specialty [2014.01.10]
Title: Gene Therapy May Hold Promise for Advanced Parkinson's Disease
Category: Health News
Created: 1/9/2014 7:35:00 PM
Last Editorial Review: 1/10/2014 12:00:00 AM
Source: MedicineNet Hoarseness Specialty [2013.12.04]
Title: Parkinson's Disease
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 12/4/2013 12:00:00 AM
Parkinson's Disease Pictures Slideshow: Symptoms, Stages and Treatment
Source: MedicineNet Tremor Specialty [2013.11.21]
Title: Parkinson's Disease Pictures Slideshow: Symptoms, Stages and Treatment
Created: 8/16/2011 6:25:00 PM
Last Editorial Review: 11/21/2013 12:00:00 AM
Published Studies Related to Eldepryl (Selegiline)
The relationship between depression and regional cerebral blood flow in Parkinson's disease and the effect of selegiline treatment. [2011.07]
OBJECTIVES: We examined the relationship between severity of depression in Parkinson's disease (PD) and regional cerebral blood flow (rCBF) using single photon emission computed tomography (SPECT) and the reaction to levodopa-selegiline combination therapy... CONCLUSIONS: These results indicate that selegiline controlled not only worsening of motor function and cognitive function in PD but also aggravation of minor depression, and restrained a fall in whole brain rCBF. (c) 2010 John Wiley & Sons A/S.
A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers. [2010.03.01]
AIM: The primary aim of this study was to determine the safety and efficacy of the monoamine oxidase-B (MAO-B) inhibitor selegiline hydrochloride (SEL, l-Deprenyl; Eldepryl) as an aid for smoking cessation in cigarette smokers... CONCLUSIONS: Our results suggest that SEL was safe and well-tolerated by adult cigarette smokers, but did not improve smoking abstinence rates compared to PLO. Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
A double-blind, placebo-controlled, randomized clinical trial of oral selegiline
hydrochloride for smoking cessation in nicotine-dependent cigarette smokers. 
l-Deprenyl; Eldepryl) as an aid for smoking cessation in cigarette smokers... CONCLUSIONS: Our results suggest that SEL was safe and well-tolerated by adult
Selegiline and oxidative stress in HIV-associated cognitive impairment. [2009.12.08]
OBJECTIVE: To assess the effectiveness of the selegiline transdermal system (STS) in reversing HIV-induced metabolic brain injury (as measured by proton magnetic resonance spectroscopy [MRS]) and in decreasing oxidative stress, measured by CSF protein carbonyl concentration... CONCLUSION: In this 24-week study, the selegiline transdermal system (STS) had no effect on either magnetic resonance spectroscopy (MRS) metabolites or oxidative stress, as measured by CSF protein carbonyl concentration. The lack of effect on these biomarkers is also reflected in the lack of cognitive improvement in the STS groups compared to placebo. Level of evidence: This study provides Class II evidence that STS had no effect on either MRS metabolites or oxidative stress, as measured by CSF protein carbonyl concentration over a period of 24 weeks.
Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. [2008.03]
OBJECTIVE: It has been reported that selegiline, a Selective Monoamine Oxidase Inhibitor B (MAOI-B), at low doses would be helpful for treating negative symptoms in schizophrenia. Nevertheless, the results are contradictory so far. This study was designed to investigate the effect of selegiline added to risperidone as augmentation therapy in patients with chronic schizophrenia and prominent negative symptoms in an 8 week, double blind and randomized clinical trial... CONCLUSION: The present study indicates selegiline as a potential adjunctive treatment strategy for the negative symptoms of schizophrenia. Nevertheless, results of larger controlled trials are needed before recommendation for a broad clinical application can be made. (c) 2007 John Wiley & Sons, Ltd.
Clinical Trials Related to Eldepryl (Selegiline)
Evaluation of Adhesion and Dermal Tolerability of EMSAM [Completed]
Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression [Recruiting]
The primary purpose of your participation in this study is to help answer the following
research question: Whether 12-week administration of EMSAM (selegiline transdermal system)
is safe and effective for the treatment of adolescents (aged 12 through 17 years) with Major
PK Comparison of 6mg and 12mg EMSAM in Elderly vs. Non-Elderly [Completed]
Evaluate the effect of age on the PK of two different doses of EMSAM.
Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior [Recruiting]
No medications are currently available for treatment of psychostimulant addiction, a
compulsive preoccupation with use of cocaine and related compounds. Donepezil is a
medication that is currently prescribed for Alzheimer's disease, and selegiline is a
medication used for treatment of Parkinson's Disease. Both of these medications can
decrease the amount of cocaine injections that laboratory animals choose to inject by vein.
This project will determine if combined treatment with donepezil and selegiline can also
decrease cocaine-motivated behavior for human subjects in a laboratory setting.
Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients [Active, not recruiting]
A decrease in mental function often occurs in patients with HIV. Antiretroviral (ARV) drugs
are used to treat this but are not entirely effective. Some other therapy could play a role.
The drug selegiline in its pill form is used to treat Parkinson's disease, a serious brain
disorder. It is believed this drug might protect the brain and repair some damage. This study
will use this drug in a "patch" form, which has not been approved by the Food and Drug
Administration (FDA), to see if it helps with decreased mental function in patients with HIV.
The purpose of this study is to evaluate the use of selegiline transdermal system (STS) in
the treatment of decreased mental function in patients with HIV.